ANI Pharmaceuticals loses jury verdict in royalty dispute with CG Oncology; no damages awarded

ANI PHARMACEUTICALS INC

Jury returned verdict on July 29, 2025 awarding no damages to ANI on its unjust enrichment counterclaim against CG Oncology.
Court previously granted CG Oncology's partial summary judgment on Brulotte defense, finding royalty provision unenforceable.
ANI intends to challenge the verdict through post-trial motions and/or an appeal.
Case stems from a 2010 Agreement for a 5% royalty on worldwide net sales of cretostimogene.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.